ARTICLE | Financial News
Synthorx proposes $100M IPO ahead of synthetic IL-2 clinical testing
November 16, 2018 5:43 PM UTC
Synthetic biology company Synthorx Inc. (La Jolla, Calif.) proposed to raise $100 million in a NASDAQ IPO, according to an SEC filing from Nov. 13.
Synthorx is using synthetic biology to develop a pipeline of Synthorin cytokines. Synthorins contain unnatural amino acid sequences and are engineered to have extended half-lives and increased receptor specificity (see "Base Instincts")...
BCIQ Company Profiles
BCIQ Target Profiles